In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lab21 gets rights to THEROS test from bioTheranostics

Executive Summary

BioTheranostics, a molecular testing division of bioMerieux and the Merieux Alliance, has granted Lab21 (UK diagnostics and testing services start-up formerly known as Newmarket Laboratories) rights to sell its THEROS CancerTYPE ID (CTID) test for two years in the UK, Ireland, and the Middle East.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies